trastuzumab and pertuzumab as maintenance therapy for metastatic HER2+ breast cancer (HER2CLIMB-05)

People with metastatic HER2+ breast cancer are asked to participate in a research study being conducted by Montefiore Medical Center.

You may be eligible to participate in this study if you:

  • Are a male or female at least 18 years of age
  • Have centrally confirmed HER2+ breast carcinoma
  • Have unresectable locally advanced or metastatic disease
  • Have received 4-8 cycles (21-day cycles) of previous treatment with trastuzumab, pertuzumab, and taxane as first-line therapy for advanced HER2+ breast cancer with no evidence of disease progression
  • Have adequate baseline hematologic parameters
  • Have adequate hepatic function

You may NOT participate in this study if you:

  • Are unable for any reason to undergo contrast MRI of the brain
  • Have a history of allergic reactions to trastuzumab, pertuzumab, or compounds chemically or biologically similar to tucatinib
  • Have inability to swallow pills
  • Have known immunodeficiency virus (HIV) infection or are positive for Hepatitis B
  • Have current conditions of symptomatic congestive heart failure, unstable angina pectoris, uncontrolled hypertension, or cardiac arrhythmia or history of myocardial infarction
  • Have any untreated brain lesion
  • Are pregnant, breastfeeding, or planning a pregnancy

Contact Information

Ana Bernal Guarin, Study Coordinator

1695 Eastchester Road, Rm 503 Bronx, NY 10461
Phone: (718) 405-8428